Objective In this pilot study, the effect of sildenafi l on digital ulcer (DU) healing and related clinical symptoms was analysed.
INTRODUCTION
Systemic sclerosis (SSc) is a devastating disease with a high impact on quality of life and prognosis. Vasculopathy is an early and prominent feature and is refl ected by Raynaud's phenomenon (RP), the presence of digital ulcers (DUs) and pulmonary arterial hypertension (PAH 1 ). Recent therapeutic advances suggest common pathogenic mechanisms and a role for endothelin receptor activation in SSc-associated vasculopathy. 2 However, endothelin receptor blockers such as the dual endothelin receptor type A/B blocker bosentan are effective in the prevention of DUs, but are not able to heal DUs, indicating different mechanisms for prevention and ulcer healing. 3 Intravenous iloprost is often used for the treatment of DUs, but its effect on the prevention of DUs has not been studied to date. There is also a subgroup of patients that do not respond to iloprost treatment. 4 Reduced levels of nitric oxide have also been proposed to play a role in the pathogenesis of vascular disease in systemic sclerosis. 5 Therefore, sildenafi l as a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specifi c phosphodiesterase type 5 and potent agent to increase the endogenous NO levels is an attractive candidate for the treatment of SSc-associated vasculopathy. Indeed, sildenafi l is approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of PAH. The highest dose of sildenafi l recommended for the treatment of PAH is 60 mg daily; however, several studies suggest a higher effect by increasing the dose. 6 7 In a placebo-controlled crossover study, 50 mg sildenafi l twice daily for 4 weeks was shown to be effective for the treatment of RP. 8 Furthermore, some case reports have suggested an effect on DU healing in SSc. 9 10 Therefore, we conducted a pilot study analysing the effect of sildenafi l on healing of SSc-associated DUs refractory to other treatments.
PATIENTS AND METHODS
A total of 19 patients with SSc (mean age 51 years) fulfi lling the American College of Rheumatology (ACR) criteria for systemic sclerosis, assessed according to the European League Against Rheumatism (EULAR) Scleroderma Trials And Research (EUSTAR) criteria, 11 and experiencing severe rhagades (n=1) or digital ulcers (n=18) refractory to treatment were treated with the maximally tolerated sildenafi l doses (up to 150 mg) for a maximum of 6 months. Inclusion criteria were stable treatment with vasoactive and immunosuppressive drugs for 3 months. Current smokers, patients with gangrene, a history of gastric ulcers during the last 3 months, cardiac ejection fraction below 25%, patients with severe organ involvement or other uncontrolled diseases were excluded. DUs were defi ned as a loss of epidermis and dermis. The demographic data are shown in table 1.
The study was conducted between 2004 and 2007. Two patients were treated outside of the study with the intention to heal digital ulcers refractory to other treatments. The other 17 patients were treated as part of a prospective, open, single-centre study. Here, the primary outcome parameter was DU healing. Secondary end points were effects on Raynaud's phenomenon by using a visual analogue scale (VAS), the prevention of new ulcers, changes in VAS scores for pain, activity and experiencing ulcers, the improvement of rhagades, Scleroderma Health Assessment Questionnaire (SHAQ) indices and the occurrence of sildenafi l-related adverse effects. Drop out criteria/fi nal end points were any changes in the immunosuppressive treatments, no response on ulcer healing within 1 month, or escalation of medication with vascular effects. Relevant macrovasculopathy responsible for DUs was excluded by angiography or duplex sonography. 12 Nine patients treated for 6 months by sildenafi l received a second angiography.
The study was approved by the local ethical committee (SDN-D-002G) and published as a clinical trial (NCT00624273). Patients signed an individual informed consent.
Statistics
A paired Wilcoxon test was used to identify the effect of sildenafi l on digital ulcers and VAS for clinical symptoms. Graph Pad Prism V.3.02 (Graph Pad Software, San Diego, California, USA) for Microsoft Windows was used.
RESULTS
Three patients did not receive sildenafi l for more than 1 month due to myositis requiring immunosuppression (n=1), the reoccurrence of atrial fi brillation (n=1) and infection of an ulcer with a multiresistant staphylococcus (n=1), and were excluded from further analyses. In the remaining 16 patients, the mean sildenafi l dose was 114 mg/day, and the mean duration of treatment was 5.2 months. At baseline, 49 ulcers were present (mean 3.1/ patient). Most patients showed a rapid response reaching a minimum of DUs within 3 months without differences in SSc subtype (fi gure 1A,B; fi gure 2). The minimal number of DUs was achieved in each patient at different time points; minimally nine DUs were present (mean 0.6 ulcers/patients, p<0.001 compared to initial numbers, table 1). At the end of sildenafi l treatment, 17 digital ulcers were detectable (mean 1.1/patient), which was different from the number of ulcers at baseline (p<0.001, table 1).
During sildenafi l treatment, 9 patients developed 12 new DUs resulting in treatment being stopped in 3 patients. In one of these patients a diagnosis of calcinosis was made. A total of 12 patients were treated for 6 months. VAS scores for RP, pain and activity signifi cantly improved (p=0.003, p=0.002 and p=0.05, respectively) with sildenafi l treatment (fi gure 1C-F). There was also a tendency for changes in the disability score due to the DUs (p=0.08). SHAQ Disability Index (SHAQ-DI) scores available from 11 patients improved from a mean of 0.6 (SD 0.52) to 0.42 (SD 0.32) but failed to reach statistical signifi cance (p=0.14). In the nine patients that received angiography before and after treatment, one responder showed an improvement of vascular pathology (not shown). Severe rhagades disappeared by sildenafi l in the one affected patient. Of the 14 patients with ‡Indicates cessation of treatment due to other events with possible impact on the effect of treatment (ulcer infection, cyclophosphamide use). §Indicates patients with development of new digital ulcer or calcinosis and no signifi cant improvement by treatment. AA, autoamputation; AB, α blocker; AC, anticoagulation; ACE, angiotensin converting enzyme inhibitor; AF, atrial fi brillation; ASA, acetyl salicylic acid; ATB, angiotensin receptor blocker; AZA, azathioprine; BWI, body weight increase; CCB, calcium channel blockers; compl heal, number of ulcers completely healed; CYC, cyclophosphamide; DD, disease duration; Dizz, dizziness; Dys, dyspnoea; E, Oedema; Fl, fl ush; HQ, hydroxycloroquine; MP, muscle pain; P, prednisone (mg/day); Pa, palpitations; PC, intravenous prostacyclin (weeks with maximally tolerated dose for 6 h/day); PP, plasmaphereses; PX, pentoxyphylline; RRR, reduction of RR (arterial hypertension) medication; Rx, refl ux; SG, surgery; SL, sympathicolysis.
follow-up data available, 7 patients developed 15 DUs within 3 months, and 3 patients took sildenafi l outside of the study. Mild side effects were common and were present in 9 out of 19 patients, but resulted in a discontinuation of the treatment only in the 2 male patients (table 1). In three patients with arterial hypertension, the antihypertensive treatment was reduced during sildenafi l treatment.
DISCUSSION
In a previous single-centre placebo-controlled crossover study, sildenafi l was shown to improve the capillary blood fl ow and RP. As suggested by a few patients with DUs, sildenafi l could provide a useful therapeutic approach for DU healing. In this prospective, open pilot study, maximally tolerated sildenafi l doses seem to be effective in DU healing. The effect was rapid, and maximum benefi t was reached in the fi rst few months. Furthermore, the study confi rmed the benefi cial effect of sildenafi l on RP and microvasculopathy. DUs are a very severe complication with a high impact on the quality of life in patients with SSc. At present, there is no approved treatment for the healing of DUs. The dual endothelin-1 receptor antagonist has failed to be effective in ulcer healing. 3 However, different studies have shown the effect of bosentan in preventing the development of new DUs. 3 13 In the present study, sildenafi l shows benefi t in DU healing, confi rming case reports and initial observations in which sildenafi l was given only for a few weeks. 8 In our study, patients were treated for up to 6 months. Within this period, a signifi cant proportion of patients developed new DUs, suggesting a failure of sildenafi l to prevent new structural defects. Furthermore, only one patient had mild improvement by angiography. As already suggested by others, different pathogenetic mechanisms could be responsible for prevention or DU healing. 2 14 Therefore, as also discussed for the treatment of PAH, combination treatments targeting different pathogenic mechanisms could provide a more valuable and effective tool for further treatments.
A major limitation of this study is the lack of a placebo group. When compared to the placebo group of the 'Rheumatoid Arthritis PreventIon of structural Damage 1' (RAPID 1) study in which about 10% of ulcers healed per month, 3 the number of ulcers healed was higher in our sildenafi l group. However, direct comparison with other trial data provide only limited information due to differing study designs. Furthermore, most of the patients treated here had been refractory to previous treatments. In conclusion, this pilot study indicates benefi cial and rapid effects in the treatment of DUs. Moreover, sildenafi l decreases the burden of RP and associated symptoms. The data encourages controlled studies, and combining a preventive as well as a curative treatment would be a valuable approach to treat DUs in patients with SSc.
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Therefore, our study population could represent a subgroup of patients with SSc truly responding to sildenafi l treatment.
For treatment of PAH or erectile dysfunction, lower doses of sildenafi l are usually used. In our study, maximally tolerated doses were given for the treatment of DUs. Treatment was well tolerated and side effects were not dose related. The two male patients who discontinued the drug due to side effects received low sildenafi l doses (2×25 mg/day), suggesting a higher sensitivity to the drug other than the use of unconventionally high doses. The incidence of peripheral oedema, the presence of dyspnoea and reoccurrence of atrial fi brillation suggest increased blood fl ow and fl uid overload in few patients. This remains to be further evaluated since phosphodiesterase-5 inhibitors were also successfully used to treat pulmonary oedema. 15 
